BCII (BCII) Stock Price & Analysis
BCII (BCII) rose 0.00% to USD 0.01 as of July 25, 2026 at 06:10 UTC, according to Nexqual real-time market data.
BCII last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 171,548 shares. Market capitalization is $735,863, with a 52-week range of USD 0.01–0.02 (OID). Source: Nexqual, July 25, 2026 at 06:10 UTC.
Key Statistics (as of July 25, 2026 at 06:10 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.02 |
| Volume | 171,548 shares |
| Market Cap | $735,863 |
| Exchange | OID |
Technical Analysis (BCII)
Nexqual's technical model rates BCII "STRONG SELL" based on 1 bullish and 6 bearish signals across 125 daily candles, as of July 25, 2026 at 06:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.71 (neutral) |
| vs SMA50 | Below (USD 0.01) |
| MACD | -0 (negative) |
Analyst Ratings (BCII)
Wall Street analysts rate BCII "None", per Nexqual as of July 25, 2026 at 06:10 UTC.
| Consensus Rating | None |
|---|
Earnings (BCII)
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financials & Fundamentals (BCII)
| Total Revenue | $1.58M |
|---|---|
| Gross Margin | +79.22% |
| Operating Margin | -369.23% |
| Profit Margin | -282.68% |
| Current Ratio | 0.71 |
| Total Cash | $1.12M |
| Total Debt | $0 |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financial Health Score (BCII)
Nexqual rates BCII's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $1M cash, no debt |
| Cash Flow | Solid — Operating cash flow $4M |
| Efficiency | Mixed — No data |
Ownership (BCII)
| Insider Ownership | +51.49% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 66.90M |
| Float | 23.89M |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Leadership (BCII)
BCII is led by Andreas A. Typaldos (age 80), Executive Chairman & CEO, per Nexqual as of July 25, 2026 at 06:10 UTC.
| Executive Chairman & CEO | Andreas A. Typaldos (age 80) |
|---|---|
| President | Zack Pontgrave (age 41) |
| Director of International Sales and Marketing | John Spinelli (age 62) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRX | Adhera Therapeutics Inc. | USD 0 | ▲ 0% |
| DMGGF | DMG Blockchain Solutions Inc. | USD 0.33 | ▼ 9.7% |
| CINGF | Coinsilium Group Ltd. | USD 0.03 | ▲ 0% |
| BBKCF | BIGG Digital Assets Inc. | USD 0.05 | ▲ 9.3% |
| REGRF | New World Solutions Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:10 UTC. This page is informational and not investment advice.